MRI disease activity significantly reduced with remibrutinib vs. teriflunomide in two trials, including reductions in T2 lesion activity by 65% and 70%, and Gd+ T1 lesions by 66% across both trials¹ ...

Amgen Canada announced UPLIZNA® (inebilizumab) is now available for prescription as an add-on treatment to standard therapy for adults living ...